Biogen Inc

자세한 내용은 Biogen Inc 회사

Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).

회사 정보

회사 코드BIIB

회사 이름Biogen Inc

상장일Sep 17, 1991

설립일1997

CEOMr. Christopher A. (Chris) Viehbacher

직원 수7605

유형Ordinary Share

회계 연도 종료Sep 17

주소225 Binney Street

도시CAMBRIDGE

증권 거래소NASDAQ Global Select Consolidated

국가United States of America

우편 번호02142

전화17814642000

웹사이트https://www.biogen.com/

회사 코드BIIB

상장일Sep 17, 1991

설립일1997

회사 임원

이름

이름/직위

직위

주식 보유

변동

Ms. Susan H. Alexander, Esq., J.D.

Executive Vice President, Chief Legal Officer

56.35K

+55.38%

Ms. Caroline D. Dorsa

Independent Chairman of the Board

26.06K

+4.98%

Dr. Ginger Gregory, Ph.D.

Chief Human Resources Officer, Executive Vice President

17.50K

+28.86%

Ms. Nicole Murphy

Executive Vice President - Pharmaceutical Operations and Technology

14.22K

+1.19%

Mr. Rachid Izzar

Executive Vice President, Head of Global Product Strategy and Commercialization

13.45K

+38.65%

Dr. Stephen A. Sherwin, M.D.

Independent Director

9.98K

-3.67%

Mr. Jesus B. Mantas

Independent Director

6.05K

-5.91%

Ms. Priya Singhal, M.D.

Executive Vice President, Head of Development

5.43K

-41.22%

Dr. Maria C. Freire, Ph.D.

Independent Director

3.10K

-10.90%

Dr. Adam James Keeney, Ph.D.

Executive Vice President, Head of Corporate Development

2.38K

+25.47%

이름

이름/직위

직위

주식 보유

변동

Ms. Susan H. Alexander, Esq., J.D.

Executive Vice President, Chief Legal Officer

56.35K

+55.38%

Ms. Caroline D. Dorsa

Independent Chairman of the Board

26.06K

+4.98%

Dr. Ginger Gregory, Ph.D.

Chief Human Resources Officer, Executive Vice President

17.50K

+28.86%

Ms. Nicole Murphy

Executive Vice President - Pharmaceutical Operations and Technology

14.22K

+1.19%

Mr. Rachid Izzar

Executive Vice President, Head of Global Product Strategy and Commercialization

13.45K

+38.65%

Dr. Stephen A. Sherwin, M.D.

Independent Director

9.98K

-3.67%

수익 분석

통화: USD업데이트 시간: Sun, Apr 6

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

사업별USD

이름

수익

비율

Spinal Muscular Atrophy-SPINRAZA

1.99B

20.55%

MS product revenues-TYSABRI

1.72B

17.72%

MS product revenues-Fumarate

1.60B

16.49%

MS product revenues-Interferon

968.00M

10.00%

Biosimilar product revenues-BENEPALI

479.10M

4.95%

Other

2.93B

30.29%

지역별USD

이름

수익

비율

Rest of World

3.98B

41.09%

United States

3.30B

34.08%

United states-Revenues from anti-CD20 therapeutic

1.75B

18.09%

Rest of World-Other revenues

652.60M

6.74%

사업별

지역별

사업별USD

이름

수익

비율

Spinal Muscular Atrophy-SPINRAZA

1.99B

20.55%

MS product revenues-TYSABRI

1.72B

17.72%

MS product revenues-Fumarate

1.60B

16.49%

MS product revenues-Interferon

968.00M

10.00%

Biosimilar product revenues-BENEPALI

479.10M

4.95%

Other

2.93B

30.29%

주주

업데이트 시간: Sat, May 17

주주 통계

유형

주주 통계

주주

비율

The Vanguard Group, Inc.

11.57%

PRIMECAP Management Company

10.88%

BlackRock Institutional Trust Company, N.A.

5.94%

State Street Global Advisors (US)

5.05%

Wellington Management Company, LLP

3.19%

Other

63.37%

주주 통계

주주

비율

The Vanguard Group, Inc.

11.57%

PRIMECAP Management Company

10.88%

BlackRock Institutional Trust Company, N.A.

5.94%

State Street Global Advisors (US)

5.05%

Wellington Management Company, LLP

3.19%

Other

63.37%

유형

주주

비율

Investment Advisor

40.61%

Investment Advisor/Hedge Fund

37.30%

Hedge Fund

6.51%

Pension Fund

2.50%

Research Firm

2.41%

Bank and Trust

1.79%

Sovereign Wealth Fund

1.64%

Individual Investor

0.16%

Family Office

0.08%

Other

7.00%

기관 주식 보유

업데이트 시간: Mon, Jan 20

보고 기간

기관 수

보유 주식

비율

변동

2025Q1

2101

138.36M

94.43%

-9.08M

2024Q4

2130

138.58M

94.69%

-5.19M

2024Q3

2109

135.95M

93.33%

-6.54M

2024Q2

2116

135.72M

93.21%

-7.14M

2024Q1

2121

136.44M

93.87%

-5.95M

2023Q4

2151

135.61M

93.59%

-2.07M

2023Q3

2177

132.42M

91.43%

-7.53M

2023Q2

2240

133.77M

92.42%

-4.86M

2023Q1

2280

132.71M

91.84%

-5.88M

2022Q4

2292

132.00M

91.64%

-4.78M

주주 활동

이름

보유 주식

비율

변동

Chg %

날짜

The Vanguard Group, Inc.

16.68M

11.39%

+1.13K

+0.01%

Dec 31, 2024

PRIMECAP Management Company

16.05M

10.96%

-268.87K

-1.65%

Dec 31, 2024

BlackRock Institutional Trust Company, N.A.

8.59M

5.87%

+23.69K

+0.28%

Dec 31, 2024

State Street Global Advisors (US)

7.40M

5.05%

+53.29K

+0.73%

Dec 31, 2024

Wellington Management Company, LLP

4.93M

3.37%

-200.47K

-3.91%

Dec 31, 2024

Geode Capital Management, L.L.C.

3.70M

2.52%

+82.46K

+2.28%

Dec 31, 2024

Invesco Capital Management (QQQ Trust)

3.01M

2.06%

+40.53K

+1.36%

Feb 28, 2025

T. Rowe Price Investment Management, Inc.

3.10M

2.12%

-1.16M

-27.17%

Dec 31, 2024

Norges Bank Investment Management (NBIM)

2.33M

1.59%

+246.45K

+11.86%

Dec 31, 2024

Invesco Capital Management LLC

1.89M

1.29%

+471.30K

+33.33%

Dec 31, 2024

132.750USD

Biogen Inc

132.750

개요

회사